<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2408">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374656</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00249598</org_study_id>
    <nct_id>NCT04374656</nct_id>
  </id_info>
  <brief_title>Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic</brief_title>
  <official_title>Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting With Conjunctivitis to the Ophthalmology Clinics During the COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified, highly
      contagious RNA virus causing respiratory infectious disease, Coronavirus Disease 2019
      (COVID-19). Conjunctivitis has been reported as a rare finding of the disease, and
      preliminary studies showed that the virus RNA could be detected in ocular secretions using
      polymerase chain reaction (PCR) assays when conjunctivitis present. This study aims to
      estimate the proportion of SARS-CoV-2 associated conjunctivitis among patients with suspected
      viral conjunctivitis presented to the ophthalmology clinics of Wilmer Eye Institute during
      the COVID-19 pandemic. The investigators also aim to identify whether SARS-CoV-2 associated
      conjunctivitis is an isolated finding or an early sign of COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of conjunctival samples tested positive for SARS-CoV-2</measure>
    <time_frame>1 year</time_frame>
    <description>Number of conjunctival samples with positive PCR divided by the total number of conjunctival samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of nasal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples</measure>
    <time_frame>1 year</time_frame>
    <description>Number of nasal samples with positive PCR divided by the number of conjunctival samples with positive PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of nasopharyngeal samples tested positive for SARS-CoV-2 among patients with positive conjunctival samples</measure>
    <time_frame>1 year</time_frame>
    <description>Number of nasopharyngeal samples with positive PCR divided by the number of conjunctival samples with positive PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of development of COVID-19 in the study patient population</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients developed COVID-19 divided by the number of the study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive conjunctival sample rate in patient developed COVID-19</measure>
    <time_frame>1 year</time_frame>
    <description>Number of conjunctival samples with positive PCR divided by the number of patients developed COVID-19</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Conjunctivitis</condition>
  <condition>SARS-CoV-2</condition>
  <condition>COVID-19</condition>
  <condition>Ocular Infection, Viral</condition>
  <condition>Ocular Inflammation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Conjunctival, nasal, and nasopharyngeal swabs will be taken for PCR testing. Tear samples
      will be collected to detect certain inflammatory markers and specific proteins.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients present or are referred to the ophthalmology clinic due to red eye complaints,
        suspected viral conjunctivitis, or keratoconjunctivitis will be consecutively approached
        and recruited if they show a willingness to participate.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years old or older

          -  Willingness to participate

          -  Presents with red eye complaint

        Exclusion Criteria:

          -  Adults lacking capacity to consent

          -  Adults with special needs due to physical, medical, developmental or cognitive
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sezen Karakus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilmer Eye Institute at Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sezen Karakus, MD</last_name>
    <phone>410-955-5080</phone>
    <email>skarakus@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sezen Karakus, MD</last_name>
      <email>skarakus@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Sezen Karakus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Behrens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elia Duh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Eberhart, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Foster, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uri Soiberman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>conjunctivitis</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Ocular Infection</keyword>
  <keyword>viral conjunctivitis</keyword>
  <keyword>ocular inflammation</keyword>
  <keyword>conjunctival swab</keyword>
  <keyword>PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Eye Infections, Viral</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

